Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

May 13, 2020May 13, 2020

Zejula-Avastin Combo Treating Advanced Cancer Patients in Phase 2 Trial

News

Zejula (niraparib) given in combination with Avastin (bevacizumab) shows promising safety and efficacy at delaying disease progression in women with advanced ovarian cancer who had responded to a first-line platinum-based ... Read more

May 6, 2020May 6, 2020

STRO-002 Continues to Show Promise in Advanced Ovarian Cancer, Early Trial Results Show

News

STRO-002, an investigational antibody-drug conjugate, continues to show promising safety and anti-tumor activity in women with advanced ovarian cancer, according to preliminary data from a Phase 1 clinical trial. ... Read more

April 15, 2020April 15, 2020

Antibody-drug Conjugate XMT-1536 Shows Promise for Ovarian Cancer in Phase 1 Trial

News

Treatment with XMT-1536 appears to be safe, with promising responses shown in heavily pretreated patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma in a Phase 1 ... Read more

November 13, 2019December 5, 2019

Opdivo-Avastin Combo Safe, Has Strong Activity in Relapsed Ovarian Cancer Patients, Phase 2 Trial Shows

News

A combination of Opdivo (nivolumab) and Avastin (bevacizumab) is safe and has strong clinical activity in women with relapsed ovarian cancer, especially among those whose tumors were sensitive to ... Read more

October 25, 2019

FDA Approves Zejula as Late-Line Treatment for Recurrent Ovarian Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a late-line treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have tumors defective in ... Read more

September 27, 2019

Rubraca Extends Time to Disease Progression in Recurrent OC, Regardless of Chemo Response, Analysis Shows

News

Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless ... Read more

August 23, 2019October 16, 2019

Lynparza-Avastin Combo Cuts Risk of Disease Progression, Death in Advanced OC, Phase 3 Trial Shows

News

When added to Avastin (bevacizumab), Lynparza (olaparib) reduces the risk of disease progression and death in women with advanced forms of ovarian cancer who are responding to their first-line treatment ... Read more

July 15, 2019

Scientists Discover Enzyme with Key Role in Aggressive Ovarian Cancers

News

Scientists discovered a metabolic enzyme that adds methyl groups to other molecules, called nicotinamide N-methyltransferase, that plays an important role in the progression of high-grade serous carcinoma, the most ... Read more

March 25, 2019

Uterine Fluid Analysis May Aid in Early Diagnosis of Aggressive OC

News

Proteomic analysis — the characterization of all proteins present in a cell at a given time — in liquid biopsies from the womb may facilitate the early diagnosis of ... Read more

March 18, 2019

GEN-1 Added to Chemo Shows Benefits in Newly Diagnosed Advanced OC

News

Adding Celsion‘s GEN-1 to standard chemotherapy — given prior to surgery — stops disease progression in patients with newly diagnosed advanced ovarian cancer and helps remove the tumor successfully during ... Read more

Pin It on Pinterest